Compare BLTE & G Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLTE | G |
|---|---|---|
| Founded | 2018 | 1997 |
| Country | United States | Bermuda |
| Employees | N/A | 140000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 5.8B |
| IPO Year | 2021 | 2007 |
| Metric | BLTE | G |
|---|---|---|
| Price | $158.49 | $34.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $198.00 | $49.50 |
| AVG Volume (30 Days) | 117.4K | ★ 2.4M |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ 9.82 |
| EPS | N/A | ★ 3.13 |
| Revenue | N/A | ★ $2,279,438,000.00 |
| Revenue This Year | N/A | $9.20 |
| Revenue Next Year | $492.11 | $7.27 |
| P/E Ratio | ★ N/A | $10.83 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $56.68 | $33.53 |
| 52 Week High | $200.00 | $50.24 |
| Indicator | BLTE | G |
|---|---|---|
| Relative Strength Index (RSI) | 43.63 | 38.70 |
| Support Level | $157.63 | $34.36 |
| Resistance Level | $161.28 | $38.03 |
| Average True Range (ATR) | 6.26 | 1.04 |
| MACD | -1.15 | -0.11 |
| Stochastic Oscillator | 17.27 | 29.40 |
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
Genpact Ltd is an agentic, technology-solutions company offering digital transformation, data-driven operations, and technology-enabled services across multiple industries. Its core business services include decision support services; technology services like application lifecycle management, platform customization, and support, etc; and digital operations optimizing business processes. Genpact also offers data engineering, data management, and domain-based AI and generative AI solutions; develops new technology solutions for clients; and offers agentic solutions and technology consulting services. Its reportable segments are: High Tech and Manufacturing, which generate maximum revenue, Financial Services, and Consumer and Healthcare. Geographically, it derives maximum revenue from India.